References
- Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother 1998;32:588-98, 601.
- Hull RD, Raskob GE, Pineo GF, Green SD, Throwbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975–82.
- Hull RD, Raskob GE, Rosenloom D, Pineo GF, Lerner RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med 1997;157:289–94.
- Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein throm-bosis. N Engl J Med 1996;334:677–81.
- Hallert C, Blomqvist K. Förenklad trombosbehandling i öppen yard. Ugmolekylärt heparin subkutant i en daglig dos (Simplified thrombosis treatment in outpatient care. Low-molecular-weight heparin subcutaneously in a daily dose). Läkartidningen 1995;92:3011–3.
- Lindmarker P, Holmstöm M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J Intern Med 1996;240:395–401.
- van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Miler HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis: an economic evaluation. Thromb Haemost 1998;79:259–63.
- Roger M, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombo-sis. CMAJ 1998;159:931–8.
- Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparin compared with unfractio-nated heparin for acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999;130:789–99.
- Dunn AS, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks H, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001;110:458–62.
- Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926–32.
- Kentson M, Hailed C, Engquist L, Hansen S, Bäckman K, Carlsson P. Randomised study comparing treatment of deep venous thrombosis outside hospital with inpatient hospital treatment using once-daily subcutaneous dalteparin. I. Health-related quality of life. Haemostasis 2000;30(Suppl 1):6.
- Zelen M. A new design for randomized clinical trials. N Engl J Med 1979;300:1242–5.
- Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–73.
- Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inform J 1991;25:411–24.
- The National Board of Health and Welfare. The Swedish Hospital Discharge Register 1996. Stockholm, 1999.
- Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with un-fractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized controlled trials. Ann Intern Med 1999;130:800–9.